OTC : IVEVF

Inventiva S.A.

$3.59 USD

$0 (0.0%)

Volume
100
Average Volume
1
Market Capitalization
$499.23M
P/E Ratio
-2.00
Dividend Yield
0.00%
Price Target
Year High
$5.75
Year Low
$2.28
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$3.16
Company Overview

OTC

Andrew Obenshain

Biotechnology

Healthcare

IVEVF

77

FR

USD

https://www.inventivapharma.com

33 3 80 44 75 00

N/A

0001756594

Liquidity Metrics

-2.10

3.16

3.16

1.28

0.00

Sales & Valuation

$4.48M

117.87

-84.88

-5.01

-0.17

Profitability

-$1.9

-$354.01M

-7899.58%

-7949.86%

1870.38%

-141.93%

P/E Metrics

-2.00

-0.15

-0.15

Analyst Price Target & Rating

N/A

0/5

4 Analysts

%

Financial Health Scores

-3.23

3/9

$167.09M

$249.51M

$278.03M

-$232.53M

Key Metrics (TTM)

$488.98M

109.07

-3.67

3.16

1870.38%

-66.18%

-14.63%

-19.94%

-2520 days

Company Executives
Name Title
Martine Zimmermann Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs
Andrew Obenshain Chief Executive Officer
Axel-Sven Malkomes Chief Financial Officer
Jason A. Campagna President of Research and Development & Chief Medical Officer
Jean Volatier Executive VP Finance & Corporate Social Responsibility
Nazira Amra Chief Commercial Strategy Officer
Pamela Herbster Chief People Officer
Pascaline Clerc Executive Vice President of External and Corporate Affairs
Susan Coles Chief Legal Officer
Pierre Broqua Co-Founder
Poll Results

No votes yet today — be the first to share your view!

About Inventiva S.A. (OTC:IVEVF) Stock

Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other diseases. Its leading drug candidate, Lanifibranor, has successfully completed Phase IIb clinical trials for NASH treatment. The company is also advancing Odiparcil, which has concluded Phase IIa clinical investigation for addressing MPS VI subtype disease. Furthermore, Inventiva maintains a pipeline of earlier-stage programs targeting oncology and other therapeutic areas. The firm has established strategic collaborations, including one with AbbVie for autoimmune diseases and another with Boehringer Ingelheim International GmbH to develop novel treatments for idiopathic pu ... lmonary fibrosis. Inventiva S.A. was founded in 2011 and is headquartered in Daix, France.

Frequently Asked Questions

What is the current Inventiva S.A. (IVEVF) stock price?

Inventiva S.A.(OTC:IVEVF) stock price is $3.59 in the last trading session. During the trading session, IVEVF stock reached the peak price of $5.75 while $2.28 was the lowest point it dropped to. The percentage change in IVEVF stock occurred in the recent session was 0.0% while the dollar amount for the price change in IVEVF stock was $0.

IVEVF's industry and sector of operation?

The OTC listed IVEVF is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of IVEVF?

Martine Zimmermann | Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs
Andrew Obenshain | Chief Executive Officer
Axel-Sven Malkomes | Chief Financial Officer
Jason A. Campagna | President of Research and Development & Chief Medical Officer
Jean Volatier | Executive VP Finance & Corporate Social Responsibility

How many employees does IVEVF have?

Number of IVEVF employees currently stands at 77. IVEVF operates from 50 rue de Dijon, Daix, BF 21121, FR.

Link for IVEVF official website?

Official Website of IVEVF is: https://www.inventivapharma.com

How do I contact IVEVF?

IVEVF could be contacted at phone #33 3 80 44 75 00 and can also be accessed through its website. IVEVF operates from 50 rue de Dijon, Daix, BF 21121, FR.

How many shares of IVEVF are traded daily?

The average number of IVEVF shares traded daily for last 3 months was 1.

What is the market cap of IVEVF currently?

The market value of IVEVF currently stands at $499.23M with its latest stock price at $3.59